Virtual Library

Start Your Search

Dimitra Grapsa



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      18P - Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features (ID 489)

      12:30 - 13:00  |  Author(s): Dimitra Grapsa

      • Abstract
      • Slides

      Background

      The immunohistochemical expression of PD-L1 protein has been evaluated as a predictor of prognosis and response to immunotherapy, with controversial results. We herein aimed to further study its clinical relevance in patients with non-small cell lung cancer (NSCLC).

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      The clinical records, pathology and molecular reports of 152 patients with histologically or cytologically confirmed NSCLC, diagnosed with early-stage or metastatic disease, were retrospectively studied. The respective archival formalin-fixed, paraffin-embedded blocks were also retrieved for immunohistochemistry (IHC) testing. PD-L1 IHC was performed using the Ventana PD-L1 (SP263) assay on an automated staining system (Ventana BenchMark ULTRA), and the results were correlated with demographic, clinicopathological and molecular features of patients.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      The most common subtype of NSCLC in our cohort was adenocarcinoma (82.2%). Overall, positive PD-L1 expression was observed in 47.4% of patients’ samples. EGFR and KRAS mutations and ALK rearrangement were observed in 13.0%, 7.1% and 5.4% of patients, respectively. The percentage of PD-L1 positive expression was significantly higher in cases with malignant pleural effusion (p = 0.026), more advanced disease stage (p = 0.045) and positive lymph node status (p = 0.049). PD-L1 staining showed no association with molecular data. Correlation of PD-L1 expression with the presence of pleural effusion (OR: 4.57; 95% CI: 1.20 – 17.39; p = 0.026) and positive lymph node status (OR: 1.95; 95% CI: 1.01 – 3.81; p = 0.048) was further confirmed in multivariate analysis.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Our study results support the independent correlation of positive expression of PD-L1 protein with adverse prognostic parameters and aggressive features, such as the presence of malignant pleural effusion and infiltrated lymph nodes.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      National and Kapodistrian University of Athens.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.